{"id":328955,"date":"2021-05-22T14:00:00","date_gmt":"2021-05-22T12:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/dupilumab-newly-approved-in-switzerland-from-12-years-of-age\/"},"modified":"2021-05-22T14:00:00","modified_gmt":"2021-05-22T12:00:00","slug":"dupilumab-newly-approved-in-switzerland-from-12-years-of-age","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/dupilumab-newly-approved-in-switzerland-from-12-years-of-age\/","title":{"rendered":"Dupilumab newly approved in Switzerland from 12 years of age"},"content":{"rendered":"

Especially in adolescents, moderate to severe atopic dermatitis is associated with a high degree of suffering. In the pivotal study, dupilumab resulted in rapid and sustained relief of skin lesions and itching. Health-related quality of life also improved significantly. Dupilumab is currently the only biologic approved in Switzerland for this patient group.<\/strong><\/p>\n

<\/p>\n

Swissmedic has extended the November 2020 marketing authorization for Dupixent\u00ae (dupilumab) for the treatment of moderate-to-severe atopic dermatitis to adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis when therapy with prescription topical medications does not provide adequate disease control or is not recommended. [1]. There is a need for effective treatment options with few side effects, particularly for adolescent patients with moderate or severe atopic dermatitis. Long-term therapy with glucocorticoids has limited efficacy and is associated with side effects such as skin atrophy. Inadequately treated atopic dermatitis can have negative effects on the physical, psychological and psychosocial levels. Anxiety and sleep disorders, as well as depression and social exclusion, are clustered among those affected [2]. “Moderate to severe atopic dermatitis can impact an adolescent’s life in many ways, affecting both their physical and psychological well-being,” said Lisa Weibel, MD, Head of the Department of Pediatric Dermatology, University Children’s Hospital Zurich [3].<\/p>\n

Fast and lasting improvement of itching and skin lesions<\/h2>\n

The Swissmedic approval of dupilumab for adolescents is based on clinical data from the LIBERTY AD program. The efficacy and safety of monotherapy with the IL4\/IL13 inhibitor at a dose of 200 mg or 300 mg every two weeks was assessed in a multicenter, randomized, double-blind, placebo-controlled study in 251 patients 12 to 17 years of age with moderate to severe atopic dermatitis who had an inadequate response to topical therapy [4]. Overview of important results after the 16-week treatment period:<\/p>\n